Today endometriosis can be treated as typical representative of multifunctional diseases with complex and comprehensive gene network.
Findings of gene polymorphism study coding the first and the second phase of detoxication in female patients with endometriosis (n=139), compared to normal female patients (n=192) have been presented.
It has been detected that presence of non-functional gene allele of the 1st of 2nd phase of xenobiotic detoxification increases the risk of endometriosis.
Taking into account the obtained results we have developed a treatment setting which included the administration of dienogest 2 mg (Vizan) and glutoxim — a drug product which facilitates detoxication of the second phase within 6 months for 33 female patients with endometriosis. The experimental group included 34 women with endometriosis, who had been administrating only Dienogest for 6 months. The patients’ state was assessed after 3, 6 months following treatment onset and after 6 months following end of treatment. Obtained results allow to make a conclusion that combination of Glutoxim and Dienogest in endometriosis treatment provide for apparent clinical effectiveness, which is consistent with Dienogest monotherapy, however it provides a longer delaying time to relapse in women if hormonal therapy is to be stopped.